NASDAQ
XGN
8 stories
$207M Market cap · 2026-10-13
The rheumatologists on the call also confirmed 2 things: 1.) XGN tests are superior in identifying lupus markers vs legacy and 2.) Myositis is critical to rule out early to avoid very serious lung issues. $XGN launches Myositis labs early next year. Confirmed the entire bull case imho.
$xgn is our largest position. Had a great call with mgmt, who I think is world class. not advice, just candor on what we own. https://t.co/z57ubc1dru
@be4_the_h3rd @JasperRidley $xgn just getting started imo
Reviewing some expert transcripts. On $XGN this is worth flagging. The Rheumatologist being interviewed confirms the bull thesis. Says he uses AVISE (XGN) for his panels bc generic tests don't work well in autoimmune, and AVISE more accurate. Flat out says that the one autoimmune marker XGN doesn't offer is for Myositis, where he uses another lab. Guess what $XGN is offering in 2027?
$XGN bio pharma revenue increased 40% yy in Q2 hitting a quarterly record. What we also love is that the stock trades for 2.5x sales vs a comp set at 10.3x. This is in advance of launching testing for Myositis which is another connective-tissue disorder that requires early diagnosis to treat and prevent serious organ damage. Rheumatologists have requested a calibrated Myositis test w/ 15x more frequency than any other test because the condition is so critical to rule out. Only $XGN will offer this and its coming in the 1H of 2027, maybe Q1 and the additional cost of launch are already baked into the cake.
How important is precise autoimmune diagnostics? How big is this market? How fast is it growing? $XGN, 2x sales. https://t.co/Q54JkIDLkQ https://t.co/a2FvxREDnN
$XGN remains a top holding for us. Even after the big move higher post a beat and raise Q2, the shares trade for a material discount versus comps. The discount is silly. Especially when we consider that they are launching a new marker for Myositis. XGN tells us that Rheumatologists are BY FAR requesting a precise diagnostic for Myositis more than any other condition. The reason is because Myositis is treatable if caught early, but problematic if not. "this is the #1 asked for product amongst our rheumatologists clinical base... it's not even close to the #2 asked for offering" $XGN trades for 2x 2026 revenues. Comps go for 10x.
Really starting to like this $XGN mgmt team.
